Mirum Pharmaceuticals Announces Results of 2026 Annual Meeting of Stockholders

Mirum Pharmaceuticals, Inc. filed an 8-K report detailing the results of its 2026 Annual Meeting of Stockholders held on June 15, 2026. During the meeting, stockholders voted on three key proposals. First, the election of three Class I directors—Lon Cardon, Ph.D., William Fairey, and Timothy Walbert—was approved, with each director set to serve until the 2029 annual meeting. Second, stockholders ratified the selection of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Finally, a non-binding advisory vote approved the compensation of the company’s named executive officers as disclosed in the proxy statement. As of the record date, April 20, 2026, there were 60,977,841 shares of common stock outstanding and entitled to vote. The filing confirms that all management proposals passed with the requisite stockholder support.